热门资讯> 正文
2025-05-15 04:28
Acrivon Therapeutics (NASDAQ: ACRV) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.66) by 22.73 percent. This is a 30.14 percent increase over losses of $(0.73) per share from the same period last year.